These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36230735)

  • 21. Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.
    Satake H; Tsuji A; Nakamura M; Ogawa M; Kotake T; Hatachi Y; Yasui H; Takagane A; Okita Y; Nakamura K; Onikubo T; Takeuchi M; Fujii M
    Int J Clin Oncol; 2018 Jun; 23(3):490-496. PubMed ID: 29464396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.
    Aranda E; Viéitez JM; Gómez-España A; Gil Calle S; Salud-Salvia A; Graña B; Garcia-Alfonso P; Rivera F; Quintero-Aldana GA; Reina-Zoilo JJ; González-Flores E; Salgado Fernández M; Guillén-Ponce C; Garcia-Carbonero R; Safont MJ; La Casta Munoa A; García-Paredes B; López López R; Sastre J; Díaz-Rubio E;
    ESMO Open; 2020 Nov; 5(6):e000944. PubMed ID: 33148620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOLFOXIRI plus biologics in advanced colorectal cancer.
    García-Alfonso P; Torres G; García G; Gallego I; Ortega L; Sandoval C; Muñoz A; Lloansí A
    Expert Opin Biol Ther; 2019 May; 19(5):411-422. PubMed ID: 30887844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis.
    Xu W; Kuang M; Gong Y; Cao C; Chen J; Tang C
    Onco Targets Ther; 2016; 9():4833-42. PubMed ID: 27536147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
    BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer].
    Committee of Colorectal Cancer, Chinese Southern Oncology Group
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Jun; 24(6):473-479. PubMed ID: 34148311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Fontanini G; Boni L; Galon J; Cremolini C;
    Lancet Oncol; 2022 Jul; 23(7):876-887. PubMed ID: 35636444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.
    Jácome AA; Kee B; Fogelman D; Dasari A; Shureiqi I; Raghav K; Morris V; Johnson B; Overman M; Wolff R; Kopetz S; Rogers J; Ahmed SU; Mehdizadeh A; Rothschild N; Eng C
    Clin Colorectal Cancer; 2020 Dec; 19(4):248-255.e6. PubMed ID: 32665092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Leal F; Ferreira FP; Sasse AD
    Clin Colorectal Cancer; 2017 Dec; 16(4):405-409.e2. PubMed ID: 28433602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
    Sunakawa Y; Fujita K; Ichikawa W; Ishida H; Yamashita K; Araki K; Miwa K; Kawara K; Akiyama Y; Yamamoto W; Nagashima F; Saji S; Sasaki Y
    Oncology; 2012; 82(4):242-8. PubMed ID: 22508373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
    De Luca R; Volpe C; Mistretta O; Paci R; Ferrera G; Caputo V; Rosati G; Cicero G
    Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5310-5317. PubMed ID: 34486707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
    Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOLFOXIRI Plus Panitumumab As First-Line Treatment of
    Modest DP; Martens UM; Riera-Knorrenschild J; Greeve J; Florschütz A; Wessendorf S; Ettrich T; Kanzler S; Nörenberg D; Ricke J; Seidensticker M; Held S; Buechner-Steudel P; Atzpodien J; Heinemann V; Seufferlein T; Tannapfel A; Reinacher-Schick AC; Geissler M
    J Clin Oncol; 2019 Dec; 37(35):3401-3411. PubMed ID: 31609637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
    Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y
    Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.
    Montagnani F; Chiriatti A; Turrisi G; Francini G; Fiorentini G
    Colorectal Dis; 2011 Aug; 13(8):846-52. PubMed ID: 20070327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    Rossini D; Boccaccino A; Sbrana A; Daniel F; Borelli B; Raimondi A; Santini D; Conca V; Tomasello G; Caponnetto S; Marmorino F; Zaniboni A; Buonadonna A; Masi G; Lonardi S; Pietrantonio F; Falcone A; Antonuzzo A; Cremolini C
    ESMO Open; 2021 Dec; 6(6):100293. PubMed ID: 34689001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis.
    Zhou M; Yu P; Hernick Davin DB; Li Y; Wang Y; Fu L; Zhang J
    Oncotarget; 2017 Sep; 8(37):62339-62348. PubMed ID: 28977949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
    Tomasello G; Petrelli F; Ghidini M; Russo A; Passalacqua R; Barni S
    JAMA Oncol; 2017 Jul; 3(7):e170278. PubMed ID: 28542671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.